Hyperactive bladder in multimorbid patients. What should be remembered?
- Authors: Korshunova E.S1,2,3, Korshunov M.N3,4
-
Affiliations:
- National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation
- Research Center of Neurology
- Central State Medical Academy of the President of the Russian Federation
- Russian-German Center for Reproduction and Clinical Embryology of Generation NEXT
- Issue: Vol 20, No 7 (2018)
- Pages: 41-45
- Section: Articles
- URL: https://journals.rcsi.science/2075-1753/article/view/95001
- DOI: https://doi.org/10.26442/2075-1753_2018.7.41-45
- ID: 95001
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
E. S Korshunova
National Medical Research Center of Radiology of the Ministry of Health of the Russian Federation; Research Center of Neurology; Central State Medical Academy of the President of the Russian Federation
Email: e_korshunova@mail.ru
канд. мед. наук, ст. науч. сотр.; доц. каф. урологии 125284, Russian Federation, Moscow, 2-i Botkinskii pr., d. 3; 125367, Russian Federation, Moscow, Volokolamskoe sh., d. 80; 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 19, str. 1a
M. N Korshunov
Central State Medical Academy of the President of the Russian Federation; Russian-German Center for Reproduction and Clinical Embryology of Generation NEXTканд. мед. наук, доц. каф. урологии; зав. андрологической лаб, Российско-немецкий центр репродукции и клинической эмбриологии 121359, Russian Federation, Moscow, ul. Marshala Timoshenko, d. 19, str. 1a; 109544, Russian Federation, Moscow, ul. Shkol'naia, d. 40-42
References
- Van den Akker M, Buntinx F, Metsemakers J.F et al. Multimorbidity in general practice: prevalence, incidence, and determinants of co-occurring chronic and recurrent diseases. J Clin Epidemiol 1998; 51 (5): 367-75.
- http://www.who.int/ageing/ageing-global-strategy-draft1-ru.pdf
- Верткин А.Л., Скотников А.С. Коморбидность. Лечащий врач. 2013; 8: 66-8.
- Von Stillfried D, Czihal T, Leibner M. Development of urology due to the demographic change. Praxisforum Urdogie. Leipzig. 29.09.2012.
- Ouslander J.G, Kane R.L, Abrass I.B. Urinary incontinence in elderly nursing home patients. JAMA 1982; 248: 1194-8.
- Diokno A.C, Estanol M.V.C, Ibrahim I.A et al. Prevalence of urinary incontinence in community dwelling men: a cross sectional nationwide epidemiological survey. Int Urol Nephrol 2007; 39: 129-36.
- Wu J.M, Vaughan C.P, Goode P.S et al. Prevalence and trends of symptomatic pelvic floor disorders in U.S. women. Obstetr Gynecol 2014; 123: 141-8.
- Stewart W.F, Van Rooyen J.B, Cundiff G.W et al. Prevalence and burden of overactive bladder in the United States. W J Urol 2003; 20: 327-36.
- Irwin D.E, Milsom I, Hunskaar S et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006; 50 (6): 1306-14.
- Brown J.S, McGhan W.F, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manag Care 2000; 6 (Suppl. 11): S574-9.
- Rubin E.B, Buehler A.E, Halpern S.D. States Worse Than Death Among Hospitalized Patients With Serious Illnesses. JAMA Intern Med 2016; 176 (10): 1557-9. doi: 10.1001/jamainternmed.2016.4362
- Лушникова Е.Л., Непомнящих Л.М., Неймарк А.И. и др. Роль структурно-функциональных изменений гладкомышечных клеток детрузора и предстательной железы в развитии гиперактивного мочевого пузыря. Фундаментальные исследования. 2012; 5 (1): 68-73.
- Коршунова Е.С. Диагностика и лечение симптомов нижних мочевых путей у больных болезнью Паркинсона в сочетании и без доброкачественной гиперплазии простаты. Автореф. дис. … канд. мед. наук. М., 2006.
- Lüthje P, Hirschberg A.L, Brauner A. Estrogenic action on innate defense mechanisms in the urinary tract. Maturitas 2014; 77 (1): 32-6. doi: 10.1016/j.maturitas.2013.10.018
- Robinson D, Cardozo L, Milsom I et al. Oestrogens and overactive bladder. Neurourol Urodyn 2014; 33 (7): 1086-91. doi: 10.1002/nau.22464
- Yamaguchi C, Sakakibara R, Uchiyama T et al. Overactive bladder in diabetes: a peripheral or central mechanism? Neurourol Urodyn 2007; 26 (6): 807-13.
- Mansfield K.J, Liu L, Mitchelson F.J et al. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes in ageing. Br J Pharm 2005; 144: 1089-99.
- Ikeda K, Kobayashi S, Suzuki M et al. M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland. Naunyn-Schmiedeberg’s Arch Pharmacol 2002; 366: 97-103.
- Pietzko A, Dimpfel W, Schwantes U, Topfmeier P. Influences of trospium chloride and oxybutynin on quantitative EEG in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 337-43.
- Katz I.R, Sands L.P, Bilker W et al. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46 (1): 8-13.
- Womack K.B, Heilman K.M. Tolterodine and memory: dry but forgetful. Arch Neurol 2003; 60 (5): 771-3.
- Callegari E, Malhotra B, Bungay P.J et al. A comprehensive non-clinical evaluation of the CNS penetration potential of antimuscarinic agents for the treatment of overactive bladder. Br J Clin Pharmacol 2011; 72 (2): 235-46. doi: 10.1111/j.1365-2125.2011.03961.x
- Ferguson D.R, Kennedy I, Burton T.J. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes - a possible sensory mechanism? J Physiol 1997; 505: 503-11.
- Hanna-Mitchell A.T, Beckel J.M, Barbadora S et al. Non-neuronal acetylcholine and urinary bladder urothelium. Life Sci 2007; 80: 2298-302.
- Kim Y, Yoshimura N, Masuda H et al. Intravesical instillation of human urine after oral administration of trospium, tolterodine and oxybutynin in a rat model of detrusor overactivity. BJU Int 2005; 97: 400-3.
- Ortiz de Montellano, Paul R. Cytochrome P450: structure, mechanism, and biochemistry. 3rd ed. New York: Kluwer Academic/Plenum Publishers, 2005.
- Guay D.R.P. Clinical pharmacokinetics of drugs used to treat urge incontinence. Clin Pharmacokinet 2003; 42: 1243-85.
- Ohtake A, Saitoh C, Yuyama H. Pharmacological characterization of a new antimuscarinic agent, solifenacin succinate, in comparison with other antimuscarinic agents. Biol Pharm Bull 2007; 30: 54-8.
- Chapple C.R, Khullar V, Gabriel Z. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008; 54: 543-62.
- Crewe H.K, Lennard M.S, Tucker G.T. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. 1992/09/01 ed. Br J Clin Pharmacol 1992; 34: 262-5.
- Yaïch M, Popon M, Médard Y. In-vitro cytochrome P450 dependent metabolism of oxybutynin to N-deethyloxybutynin in humans. Pharmacogenetics 1998; 8 (5): 449-51.
- Zanger U.M, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-41.